Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carfilzomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a multi-agent chemotherapy regimen combining seven drugs: carfilzomib (a second-generation proteasome inhibitor), thalidomide (an immunomodulatory agent), dexamethasone (a synthetic glucocorticoid corticosteroid), cisplatin (a platinum-based DNA crosslinker), doxorubicin (an anthracycline topoisomerase II inhibitor and DNA intercalator), cyclophosphamide (an alkylating agent that crosslinks DNA), and etoposide (a topoisomerase II inhibitor). This combination, sometimes referred to as KTd-PACE, is used in the treatment of multiple myeloma, particularly for relapsed or refractory cases or as part of intensive regimens for high-risk disease. Each component has a distinct mechanism of action targeting different aspects of cancer cell survival and proliferation. The regimen aims to maximize anti-myeloma efficacy by combining agents with non-overlapping mechanisms.
- Other names
- KTd-PACE
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)PSMB8 (Immunoproteasome)TOP2A (DNA topoisomerase II)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on carfilzomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carfilzomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide.